Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.

Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.


's stock had its "buy" rating restated by Noble Financial in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. They presently have a $8.00 target price on the biotechnology company's stock.



from Biotech News